Today: 23 May 2026
Why JPMorgan Chase & Co. stock is rising today: frontier-bond index plan and a Wall Street upgrade
3 February 2026
2 mins read

Why JPMorgan Chase & Co. stock is rising today: frontier-bond index plan and a Wall Street upgrade

New York, February 3, 2026, 11:43 (EST) — Regular session

  • JPM shares up about 2% near $314 in late-morning trade.
  • New frontier-market bond index plan is taking shape, sources say.
  • Baird lifts its rating to Neutral, while calling the stock pricey.

JPMorgan (NYSE:JPM) shares were up $6.11, or about 2%, at $314.25 on Tuesday after swinging between $308.15 and $316.18.

The move comes as investors reset rate bets after Donald Trump nominated Kevin Warsh to lead the Federal Reserve. Raphael Bostic said the central bank should not cut rates this year, after policymakers voted 10-2 last week to keep the benchmark rate in the 3.50%-3.75% range.

U.S. stocks were also a shade higher, but traders were still working without the usual flow of economic releases as a partial government shutdown pushed back data. The U.S. House of Representatives was set to try to pass a deal later Tuesday, while the January jobs report and the JOLTS openings report were delayed.

Other big lenders traded higher too. Bank of America rose 1.2%, Wells Fargo gained 1.9% and Citigroup added 1.2%.

On the company-specific side, sources said JPMorgan is finalising plans for a new index tracking frontier-market local-currency bonds, with an outline possibly as early as end-March and a more detailed structure around June. The proposed index would include about 20 to 25 countries and only bonds of at least $250 million equivalent, one source said, and JPMorgan declined to comment. Neuberger Berman’s Rob Drijkoningen said the performance of frontier local-currency debt suggested the asset class had been “systematically underpriced.” Reuters

Broker Robert W. Baird also upgraded JPMorgan to Neutral from Underperform and set a $280 price target. Baird said the valuation looked expensive at about 2.95 times tangible book value — a bank yardstick that strips out goodwill and other intangibles — even as it pointed to an “enviable capital position.” Investing.com

In a separate note on Monday, JPMorgan said brokers could start charging ETF managers new distribution fees as zero-commission trading and the shift from mutual funds squeeze revenues. JPMorgan put the U.S. ETF management fee pool at $21 billion and said brokers targeting 10% to 20% of expense ratios — the annual fee charged by a fund — could mean $2 billion to $4 billion in new costs, with bigger groups like BlackRock and Vanguard better positioned to negotiate than mid-sized managers such as Invesco.

JPMorgan last month posted a fourth-quarter profit that beat estimates, helped by a surge in trading revenue, but the stock slipped that day after investment banking fees missed forecasts. David Wagner at Aptus Capital Advisors said “the bar for perfection is set pretty high” for the stock. Reuters

But the rate story that helps banks can turn fast. Long-term Treasury yields are hovering around 4.30%, and a rise in the “term premium” — the extra yield investors demand to hold long bonds — has kept borrowing costs elevated; Trump has floated ways to push long-term rates down, including proposals to cap credit-card interest rates at 10%. Reuters

Next up: JPMorgan is scheduled to host a company update on Feb. 23, when executives are set to field investor questions after a firm overview presentation.

Stock Market Today

  • Haemonetics Q1 Earnings Beat Estimates Amid Strong Medical Devices Sector Performance
    May 22, 2026, 10:52 PM EDT. Haemonetics (NYSE:HAE) posted a robust Q1 with revenues of $346.4 million, up 4.8% year on year and exceeding analyst forecasts by 2.6%. The medical devices & supplies specialty sector outperformed expectations, with revenues beating consensus by 5.2% overall. Haemonetics shares rose 10.6% post-earnings to $58.27, reflecting investor confidence. Industry growth drivers include an aging population increasing demand for blood-related medical products and advances in digital health technology, while challenges remain from pricing pressures and regulatory demands. The sector saw steady stock performance, up 3.6% on average following earnings releases. STAAR Surgical also delivered strong results, highlighting sector momentum.

Latest articles

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

23 May 2026
The Dow closed at a record 50,579.70 on Friday, while the S&P 500 notched its eighth straight weekly gain. After-hours trading saw SPY, QQQ, DIA, and IWM all move lower. U.S. markets will be closed Monday for Memorial Day. Investors await Thursday’s inflation data.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

23 May 2026
IREN shares fell 2.1% to $56.83 Friday, ending a two-day rally but closing the week up 7.4%. The stock’s moves follow a $3.4 billion AI cloud deal with Nvidia and a $3 billion convertible note offering. March-quarter revenue dropped to $144.8 million, with a net loss of $247.8 million. U.S. markets close Monday for Memorial Day; trading resumes Tuesday.
AXT stock reaches record; investors weigh risk to rally

AXT stock reaches record; investors weigh risk to rally

23 May 2026
AXT shares jumped 16.37% to $140.83 on Friday, hitting a 52-week high and trading above all recent analyst targets. The surge followed strong demand for AI-linked optical networking hardware and a sharp rise in indium phosphide orders. First-quarter revenue climbed to $26.9 million, with gross margin turning positive. Management forecast Q2 profitability and a backlog over $100 million.
Thomson Reuters stock tumbles after National Bank target cut, as AI fears hit legal-data peers
Previous Story

Thomson Reuters stock tumbles after National Bank target cut, as AI fears hit legal-data peers

Merck stock rises despite cautious 2026 outlook as patent losses loom
Next Story

Merck stock rises despite cautious 2026 outlook as patent losses loom

Go toTop